Cell-Based Assays World Industry and Market Prospects 2016-2026

LONDON, August 23, 2016 /PRNewswire/ --

Products, Services, Drug Discovery, ADME, Basic Research, Organoids, Embryonic Stem Cells (ESCs), Induced Pluripotent Stem Cells (iPSCs), High-Throughput Screening (HTS)

This 197-page report provides quantitative and qualitative information on 10-years revenue forecasts to 2026 at overall world market, submarkets and national market level presented in 130 charts and discussion.

A new report by DART forecasts the world cell-based assay market will reach $6.9bn in 2020. That revenue forecast and others appear in Cell-Based Assays World Industry and Market Prospects 2016-2026: Products, Services, Drug Discovery, ADME, Basic Research, Organoids, Embryonic Stem Cells (ESCs), Induced Pluripotent Stem Cells (iPSCs), High-Throughput Screening (HTS), published in August 2016.

This 197-page report provides quantitative and qualitative information on 10-years revenue forecasts to 2026 at overall world market, submarkets and national market level presented in 130 charts and discussion.

This report provides 10-years revenue forecasts to 2026 for these submarkets:

• Products 
• Services 
• Drug discovery 
• ADME 
• Basic research 

Our work also shows individual revenue forecasts to 2026 for 11 national markets:

• United States (US) 
• Japan 
• EU leaders - Germany, France, the UK, Italy and Spain (EU5) 
• BRIC nations - Brazil, Russia, India and China. 

This report discusses the competitive landscape in the cell-based assays market, which includes discussion on SWOT, STEP, Leading Companies, and M&A activities in this market.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Find in this report, discussions on:

• R&D activities - see progress, trends and prospects in cell-based assays research and development, finding technological, clinical and commercial possibilities
• Companies, news and opinions: 
  • 11 leading companies which produce cell-based assay products
  • 9 leading CROs and cell-based assay service suppliers
  • An interview conducted by DART with expert working in cell-based assays industry:

Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

This report also provides a separate chapter on Pricing, Reimbursement, Market Access and Regulations, providing insights on these national markets:

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on http://www.dartmarkets.com/index.php/reports-pha/61-dph0002

Companies mentioned 

Affymetrix
Alliance Regenerative Medicine
AstraZeneca
ATCC
Axiogenesis
Bayer
BBC (British Broadcasting Corporation)
BD (Becton, Dickinson and Company)
Bio-Rad
BioAgilytix
BioCity
Biocroi
Biofocus
BioSeek
BioVision
BMG Labtech
CareFusion Corporation
Cell Assay Innovations (CAI)
Cellartis (Takara Bio)
Cellomics
Cellular Dynamics
Charles River Laboratories
Corning
Covance
CXR Biosciences
Cyprotex
Cytek
CYTOO
Di Carlo Laboratory
DiscoveRx
Dr. Reddy's Laboratories
ESI BIO (BioTime)
European Lead Factory
Eurostars
Evotec
Fisher Scientific
Fluofarma
ForteBio
Foundation Top Institute Pharma
GE Healthcare
GenCell
General Electric (GE)
Harlan Laboratories
Hubrecht Institute
Imagen Biotech
InSphero
Janssen
Japan Institute of Biomedical Research
Jubilant Biosys
Lead Discovery Centre GmbH
Life Technologies Corporation
Marin Biologic Laboratories
Maxcyte
Merck & Co.
Molecular Devices
Netherlands Cancer Institute
OcellO
Organovo
PerkinElmer
Pharmaceutical Product Development (PPD)
Pharmacyclics
PharmaTimes
Princeton University
Promega
ProQinase
QGel
Quintiles
ReNeuron
ReproCELL
Roche
Sanofi
Seahorse Bioscience
SGS (Société Générale de Surveillance)
Solvo
SRU Biosystems
Swiss Federal Institute of Technology
SymCel
Syncom
The European Lead Factory (ELF)
The Innovative Medicines Initiative (IMI)
The National Health Service (NHS)
The Netherlands Cancer Institute
The Scientist Magazine
Thermo Electron
Thermo Fisher Scientific
Trinity College, Dublin
Tufts Center for the Study of Drug Development
UCB (Union Chimique Belge)
UCLA (University of California, Los Angeles)
UK Department of Health
University of Kyoto
University of Oxford
University of Zurich
US Congress
US FDA
Vala Sciences
WuXi

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

SOURCE Visiongain Ltd